BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31157502)

  • 21. [Efficacy of conservative treatment of gastric lymphosarcoma].
    Zvonkov EE; Kremenetskaia AM; Kravchenko SK; Makhinia VA; Kaplanskaia IB; Obukhova TN; Samoĭlova RS; Shevelev AA; Magomedova AU; Bariakh EA; Krasil'nikova BB; Gubkin AV; Iliushkina EA; Mar'in DS; Morozova AK; Kulikov SM; Gemdzhian EG; Vorob'ev AI
    Ter Arkh; 2008; 80(7):18-26. PubMed ID: 18763589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
    Mead GM; Barrans SL; Qian W; Walewski J; Radford JA; Wolf M; Clawson SM; Stenning SP; Yule CL; Jack AS; ;
    Blood; 2008 Sep; 112(6):2248-60. PubMed ID: 18612102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
    Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
    Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost effectiveness of treating Burkitt lymphoma in Uganda.
    Denburg AE; Laher N; Mutyaba I; McGoldrick S; Kambugu J; Sessle E; Orem J; Casper C
    Cancer; 2019 Jun; 125(11):1918-1928. PubMed ID: 30840316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
    Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
    Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
    Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
    Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
    Choi KA; Lee JE; Kim YG; Kim DJ; Kim K; Ko YH; Oh HY; Kim WS; Huh W
    Ann Hematol; 2009 Jul; 88(7):639-45. PubMed ID: 19030857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy.
    Hesseling PB; Njume E; Kouya F; Katayi T; Wharin P; Tamannai M; Achu P; Kidd M; McCormick P
    Pediatr Hematol Oncol; 2012 Mar; 29(2):119-29. PubMed ID: 22376015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
    Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
    Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
    J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of survival in Nigerians with Burkitt's lymphoma.
    Kagu MB; Durosinmi ; Adeodu OO; Akinola NO; Adediran IA; Salawu L
    Afr J Med Med Sci; 2004 Sep; 33(3):195-200. PubMed ID: 15819463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
    Lacasce A; Howard O; Lib S; Fisher D; Weng A; Neuberg D; Shipp M
    Leuk Lymphoma; 2004 Apr; 45(4):761-7. PubMed ID: 15160953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP).
    Traoré F; Coze C; Atteby JJ; André N; Moreira C; Doumbe P; Ravelomanana N; Ye D; Patte C; Raquin MA; Raphael M; Lemerle J
    Pediatr Blood Cancer; 2011 Jan; 56(1):70-6. PubMed ID: 21058286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
    Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
    AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malawi pilot study of Burkitt lymphoma treatment.
    Hesseling PB; Broadhead R; Molyneux E; Borgstein E; Schneider JW; Louw M; Mansvelt EP; Wessels G
    Med Pediatr Oncol; 2003 Dec; 41(6):532-40. PubMed ID: 14595710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
    Offidani M; Corvatta L; Centurioni R; Leoni F; Malerba L; Mele A; Marconi M; Scortechini A; Masia MC; Leoni P
    Hematol J; 2003; 4(1):47-53. PubMed ID: 12692520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
    J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endemic Burkitt lymphoma of maxillofacial region: results of induction treatment with cyclophosphamide plus methotrexate in West Africa.
    Béogo R; Nacro B; Ouédraogo D; Ouoba K
    Pediatr Blood Cancer; 2011 Jul; 56(7):1068-70. PubMed ID: 21344617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.